|
Most
dysplasia cases do not need to be treated in the
first place as about 80% of them regress spontaneously.
But
as there are no morphological or molecularbiological criteria
indicating if there will be remission to
a healthy state or a progression towards cancer,
the detection of dysplasia leads to a variety
of confusion in the patients.
The
results are often excessive therapies with a large
amount of unnecessary surgery.
The
new prognostic marker cytoactiv® provides now
transparency and gives your patients the safe
feeling to be in good hands.
It
all depends on the immune system
Latest
research proves that by detecting the L1capsidprotein you can predict
the prognosis of adysplasia.
(Source:
Griesser et al.; AQCH, Vol. 26, No. 5, Oct 04, p. 241-245)
These
observations can be explained by the biological properties
of the L1 capsidprotein that can be
detected by cytoactiv®.
If
cytoactiv® proves positive, a stimmulation of the immune
system occurs resulting in a consecutive healing
of the dysplasia.
If
the L1-capsidprotein can not be detected and there
is no consecutive stimulation of the immune system
the dysplasia can develop into cancer.
|